



SHATTUCK
LABS

NEWS RELEASE

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12

2022-10-05

AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: [STTK](#)), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC's 37th Annual Meeting being held November 8th – 12th, 2022, virtually and in-person in Boston.

Presentation Details

Abstract Title: *Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity*

Abstract Number: 1203

Presenters: Suresh de Silva, Ph.D., Vice President of Product Development at Shattuck Labs and Derek Franklin, Ph.D., Scientist III at Shattuck Labs

Date: November 10th

Location: Boston, MA

Poster Hall Hours: 9:00 a.m. to 9:00 p.m. ET

Further information about the Society for Immunotherapy of Cancer Meeting can be found at: <https://www.sitcancer.org/2022/home>

About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC[®], platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's SL-172154 (SIRPα-Fc-CD40L)

program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor Contact:

Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Source: Shattuck Labs, Inc.